CRSP Similar Chart Price Prediction
The price of CRSP is predicted to go up 7.67%, based on the high correlation periods with IE. The similarity of these two price pattern on the periods is 95.77%.
CRSP
IE
Up: 7.67%Similarity: 95.77%
CRSP Revenue Forecast
CRSP EPS Forecast
CRSP FAQs
What is bull’s view on CRSP?
What is bear's view on CRSP?
What is CRSP revenue forecast for next quarter？
What is CRSP eps forecast for next quarter？
CRSP VS S&P500
Partnerships allow Crispr Therapeutics to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.
Crispr Therapeutics' Crispr/Cas9 platform has the potential to develop highly efficacious and potentially curative treatments for rare, genetic diseases with high unmet needs, which will likely lead to pricing power.
We view the company's pipeline as possessing strengthening intangible assets and assign it a positive moat trend.
CRSP Analyst's Forecast
Geoff Meacham
B of A Securities
Strong Buy
2025-01-07
Price Target
$98 → $85
Upside
+102.77%
BofA analyst Alec Stranahan lowered the firm's price target on Crispr Therapeutics to $85 from $98 and keeps a Buy rating on the shares. While political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as "markedly improved from 2022 lows." For stocks in its coverage, the firm continues to like late-stage clinical or early launch stories, although it sees Phase 1 clinical programs with derisking data and near-term catalysts as "increasingly areas of investor focus," the analyst tells investors in a sector outlook note.
